Physician profile
Anna M Lamb
NPI 1841241361
$6,712.85
in general payments reported to CMS, 2019-2025
43 companies · $257 in 2025
The $257 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,546 · 2020: $798 · 2021: $163 · 2022: $186 · 2023: $291 · 2024: $1,473 · 2025: $257.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,194 · Food and Beverage: $826.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,194.28 |
| Food and Beverage | $825.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,262.61 | 2024 | Closurefast |
| Novo Nordisk INC | $852.16 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $576.85 | 2019-2025 | |
| Glaxosmithkline, LLC. | $405.90 | 2019-2023 | Arexvy, Shingrix |
| Lilly USA, LLC | $370.85 | 2019-2024 | Mounjaro, Trulicity, Zepbound |
| Pfizer INC. | $300.15 | 2019-2024 | |
| Janssen Pharmaceuticals, INC | $298.51 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $227.14 | 2019-2023 | Fasenra |
| Otsuka America Pharmaceutical, INC. | $224.24 | 2019-2020 | |
| Allergan, INC. | $201.04 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $185.80 | 2019 | |
| Amgen INC. | $184.61 | 2019-2024 | Prolia, Evenity, Otezla |
| Gilead Sciences, INC. | $171.95 | 2019-2020 | |
| Indivior INC. | $159.90 | 2019-2025 | Sublocade |
| Mdd US Operations, LLC | $145.74 | 2019-2020 |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Lamb listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.